Cerevel Makes Progress, But Karuna Still One To Watch In Schizophrenia
Neuroscience Renaissance Continues
Competition to bring new schizophrenia therapies to market is increasing, with the need to demonstrate side-effect improvements over existing drugs especially important.
You may also be interested in...
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors
Moderna is hot on the heels of Pfizer with booster data for its COVID-19 vaccine, and could benefit from its rival being first to face potential skepticism from the US FDA over booster data for its vaccine.